

| | Standard deviation | <i>z</i> | <i>p</i> |
|-----------------------------------------------------------------------------|--------------------|----------|----------|
| Patients' evaluation of personal PML risk | 0.04 | 2.69 | 0.007 |
| Duration of natalizumab therapy | 0.44 | -0.84 | 0.40 |
| Physicians' last opinion on continuation/ discontinuation of natalizumab | 0.03 | 6.10 | < 0.001 |
| Total number of relapses during the course of study | 0.29 | 0.86 | 0.39 |
| JCV seroconversion during the course of the study | 0.56 | 2.04 | 0.04 |
| Number of treated MS patients per year | 0.001 | -0.52 | 0.60 |
| Physicians' evaluation of PML risk in general | 0.047 | 1.74 | 0.08 |